Durable molecular remission in a patient with chronic myelogenous leukemia and host-derived hematopoiesis after allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 18, Issue 4, 1996, Pages 801-804

  Wakui, M ^a   Okamoto, S ^a,c   Ishida, A ^a   Tanosaki, R ^a   Mori, T ^a   Kawai, Y ^a   Ohshima, S ^b   Ikeda, Y ^a  

^a KEIO UNIVERSITY   (Japan)

^b Tomei Atsugi Hospital   (Japan)

^c KEIO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Allogeneic bone marrow transplantation; Autologous hematopoiesis; Chronic myelogenous leukemia; Graft versus leukemia effects; Mixed chimerism; Molecular remission

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; METHOTREXATE; TACROLIMUS;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE REPORT; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; FEMALE; HEMATOPOIESIS; HUMAN; LEUKOCYTE COUNT; LYMPHOPOIESIS; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; T LYMPHOCYTE; WHOLE BODY RADIATION;

ADULT; BONE MARROW TRANSPLANTATION; CHIMERA; FEMALE; GENES, ABL; GRAFT VS HOST REACTION; HEMATOPOIESIS; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, CHRONIC-PHASE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; X CHROMOSOME; Y CHROMOSOME;

EID: 0029844189     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Thomas ED, Clift RA, Fefer A et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155-163.
2. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
3. Mackinnon S, Barnett L, Heller G, O'Reilly RJ. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 1994; 83: 3409-3416.
4. Takahashi S, Okamoto S, Shirafuji N et al. Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia. Bone Marrow Transplant 1994; 13: 239-245.
5. Kawasaki ES, Clark SS, Coyne MY et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA 1988; 85: 5698-5702.
6. Okamoto T, Kanumaru A, Wada H et al. Hematopoietic recovery from host progenitors with normal karyotype devoid of Philadelphia chromosome in a patient with CML after allogeneic BMT. Bone Marrow Transplant 1993; 12: 89-92.
7. Fyles GM, Messner HA, Lockwood G et al. Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate. Bone Marrow Transplant 1991; 8: 453-463.
8. Bertheas MF, Maraninchi D, Lafage M et al. Partial chimerism after T-cell-depleted allogeneic bone marrow transplantation in leukemic HLA-matched patients: a cytogenetic documentation. Blood 1988; 72: 89-93.
9. Baranov AE, Selidovkin GD, Butturini A, Gale RP. Hematopoietic recovery after 10-Gy acute total body radiation. Blood 1994; 83: 596-599.
10. Aman MJ, Keller U, Derigs G et al. Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist. Blood 1994; 84: 4142-4150.
11. Chudgar UH, Rundus CH, Peterson VM. Recombinant human interleukin-1 receptor antagonist protects early myeloid progenitors in a murine model of cyclophosphamide-induced myelotoxicity. Blood 1995; 85: 2393-2401.
12. Darrington DL, Vose JM, Anderson JR et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527-2534.